Q3 FY26 results: Revenue up 43%, PAT jumps to Rs 15.7 cr consol

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

NGLFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+19.0%Reaction day

₹1818.30

prior close

₹2050.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+17.7% vs market

Pharmaceuticals peers, median of 155sector+0.2%+18.8% vs sector

On the reaction day the stock moved 17.7 pts more than Nifty Microcap 250 and 18.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.1

10m

+5.6

15m

+5.6

30m

+5.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+19.0+1.3+17.7+0.2+18.8

Next day

+24.8+0.3+24.5-0.4+25.2

+18.8-0.5+19.3-1.1+19.9

+22.4+2.1+20.3+0.7+21.7

+21.4+3.1+18.3+1.3+20.1

+23.1+2.6+20.5+1.4+21.7

+26.5+0.6+25.9+0.3+26.2

15d

+24.0-1.4+25.4-2.6+26.6

+25.9-6.9+32.9-5.1+31.0

+22.6-7.7+30.3-7.9+30.6

+21.3+7.0+14.3+0.7+20.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q3 FY26 results. Consolidated revenue up 43% YoY at Rs 127.5 cr; 9M revenue at Rs 351.9 cr, up 29%. Q3 PAT at Rs 15.7 cr vs Rs 1.3 cr YoY; 9M PAT at Rs 34.6 cr vs Rs 20.3 cr. 9M EPS at Rs 55.93 vs Rs 32.87. Standalone results also strong. Clean auditor review with no qualifications. New Company Secretary Shivam Gharat appointed.

Likely market impact

Strong revenue and profit growth beats last year. Positive for shareholders; signals robust business momentum.